Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.

Autor: Sahin F; Ege University Faculty of Medicine, Department of Hematology, İzmir, Turkey., Saydam G; Ege University Faculty of Medicine, Department of Hematology, İzmir, Turkey., Cömert M; Ege University Faculty of Medicine, Department of Hematology, İzmir, Turkey., Uz B; Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey., Yavuz AS; İstanbul University Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Turan E; İstanbul University Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Yönal I; İstanbul University Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Atay H; Ondokuz Mayıs University Faculty of Medicine, Department of Hematology, Samsun, Turkey., Keltikli E; Ondokuz Mayıs University Faculty of Medicine, Department of Hematology, Samsun, Turkey., Turgut M; Ondokuz Mayıs University Faculty of Medicine, Department of Hematology, Samsun, Turkey., Pehlivan M; Gaziantep University Faculty of Medicine, Department of Hematology, Gaziantep, Turkey., Akay MO; Osmangazi University Faculty of Medicine, Department of Hematology, Eskişehir, Turkey., Gürkan E; Çukurova University Faculty of Medicine Department of Hematology and Oncology, Adana, Turkey., Paydaş S; Çukurova University Faculty of Medicine Department of Hematology and Oncology, Adana, Turkey., Kahraman S; Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey., Demirkan F; Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey., Kırkızlar O; Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey., Akpınar S; Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey., Pamuk GE; Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey., Demir M; Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey., Ozbaş HM; Karadeniz Technical University Faculty of Medicine, Department of Hematology, Trabzon, Turkey., Sönmez M; Karadeniz Technical University Faculty of Medicine, Department of Hematology, Trabzon, Turkey., Gültürk M; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Salihoğlu A; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Eşkazan AE; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Ar C; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Haydaroğlu Şahin H; Gaziantep University Faculty of Medicine, Department of Hematology, Gaziantep, Turkey., Ongören S; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Başlar Z; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Aydın Y; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Yenere MN; Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey., Tüzüner N; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Ferhanoğlu B; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey., Haznedaroglu IC; Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey., Ilhan O; Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey., Soysal T; İstanbul University Cerrahpaşa Faculty of Medicine, Department of Hematology, İstanbul, Turkey.
Jazyk: angličtina
Zdroj: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2013 Dec; Vol. 30 (4), pp. 351-8. Date of Electronic Publication: 2013 Dec 05.
DOI: 10.4274/tjh.2013.0151
Abstrakt: Objective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade. Especially, regular publication and updating of NCCN and ELN guidelines have provided enermous rationale and base for close monitorization of patients with CML. But, it is stil needed to have registry results retrospectively to evaluate daily CML practices.
Materials and Methods: In this article, we have evaluated 1133 patients' results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs.
Results: The response rate has been found relatively high in comparison with previously published articles, and we detected that there was a lack of appropriate and adequate molecular response assessment.
Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.
Conflict of Interest: None declared.
Databáze: MEDLINE
Externí odkaz: